Analysis of the efficacy and factors influencing survival of adjuvant radiotherapy for stage II-III biliary tract carcinoma.
Adjuvant radiotherapy
Biliary tract carcinoma
Surgery
Treatment modality
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
26 Oct 2023
26 Oct 2023
Historique:
received:
30
03
2023
accepted:
03
10
2023
medline:
27
10
2023
pubmed:
26
10
2023
entrez:
26
10
2023
Statut:
epublish
Résumé
To determine the efficacy of adjuvant radiotherapy for stage II-III biliary tract carcinoma. We retrospectively analyzed the data of 37 patients who underwent radical resection of biliary tract carcinomas at the Affiliated Hospital of Inner Mongolia Medical University between 2016 and 2020. We analyzed survival differences between patients who did (n = 17) and did not (n = 20) receive postoperative adjuvant radiotherapy by using Kaplan-Meier analysis. The log-rank test and Cox univariate analysis were used. The Cox proportional risk regression model was used for the multifactorial analysis of factors influencing prognosis. The median survival time (28.9 vs. 14.5 months) and the 1-year (82.40% vs. 55.0%) and 2-year survival rates (58.8% vs. 25.0%) were significantly higher among patients who received adjuvant radiotherapy than among those who did not (χ Adjuvant radiotherapy significantly improved the survival of patients with biliary tract carcinoma, and is recommended especially for patients with stage III disease, positive surgical margins, or ≥ T3.
Sections du résumé
BACKGROUND
BACKGROUND
To determine the efficacy of adjuvant radiotherapy for stage II-III biliary tract carcinoma.
METHODS
METHODS
We retrospectively analyzed the data of 37 patients who underwent radical resection of biliary tract carcinomas at the Affiliated Hospital of Inner Mongolia Medical University between 2016 and 2020. We analyzed survival differences between patients who did (n = 17) and did not (n = 20) receive postoperative adjuvant radiotherapy by using Kaplan-Meier analysis. The log-rank test and Cox univariate analysis were used. The Cox proportional risk regression model was used for the multifactorial analysis of factors influencing prognosis.
RESULTS
RESULTS
The median survival time (28.9 vs. 14.5 months) and the 1-year (82.40% vs. 55.0%) and 2-year survival rates (58.8% vs. 25.0%) were significantly higher among patients who received adjuvant radiotherapy than among those who did not (χ
CONCLUSION
CONCLUSIONS
Adjuvant radiotherapy significantly improved the survival of patients with biliary tract carcinoma, and is recommended especially for patients with stage III disease, positive surgical margins, or ≥ T3.
Identifiants
pubmed: 37880729
doi: 10.1186/s12957-023-03209-0
pii: 10.1186/s12957-023-03209-0
pmc: PMC10601315
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
339Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Gómez-España MA, Montes AF, Garcia-Carbonero R, Mercadé TM, Maurel J, Martín AM, et al. SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). Clin Transl Oncol. 2021;23:988–1000. https://doi.org/10.1007/s12094-021-02573-1 .
doi: 10.1007/s12094-021-02573-1
pubmed: 33660222
pmcid: 8058005
Doherty B, Nambudiri VE, Palmer WC. Update on the diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep. 2017;19:2. https://doi.org/10.1007/s11894-017-0542-4 .
doi: 10.1007/s11894-017-0542-4
pubmed: 28110453
Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v28–37. https://doi.org/10.1093/annonc/mdw324 .
doi: 10.1093/annonc/mdw324
pubmed: 27664259
Wang J, Narang AK, Sugar EA, Luber B, Rosati LM, Hsu CC, et al. Evaluation of adjuvant radiation therapy for resected gallbladder carcinoma: a multi-institutional experience. Ann Surg Oncol. 2015;22(Suppl 3):S1100-6. https://doi.org/10.1245/s10434-015-4685-y .
doi: 10.1245/s10434-015-4685-y
pubmed: 26224402
pmcid: 9671536
Park Y, Kim K, Park HJ, Chun HJ, Choi D, Kim K. Role of adjuvant treatment in high-risk patients following resection for gallbladder cancer. In Vivo. 2022;36:961–8. https://doi.org/10.21873/invivo.12787 .
doi: 10.21873/invivo.12787
pubmed: 35241556
pmcid: 8931922
Kumar D, Kiran NM, Khosla D. Reviewing the potential role of radiation therapy in gallbladder cancer: an update. Radiat Oncol J. 2022;40:1–8. https://doi.org/10.3857/roj.2021.00717 .
doi: 10.3857/roj.2021.00717
pubmed: 35368195
pmcid: 8984131
Patel T. Cholangiocarcinoma–controversies and challenges. Nat Rev Gastroenterol Hepatol. 2011;8:189–200. https://doi.org/10.1038/nrgastro.2011.20 .
doi: 10.1038/nrgastro.2011.20
pubmed: 21460876
pmcid: 3888819
Takahashi Y, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, et al. Surgery for recurrent biliary tract cancer: a single-center experience with 74 consecutive resections. Ann Surg. 2015;262:121–9. https://doi.org/10.1097/sla.0000000000000827 .
doi: 10.1097/sla.0000000000000827
pubmed: 25405563
Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383:2168–79. https://doi.org/10.1016/s0140-6736(13)61903-0 .
doi: 10.1016/s0140-6736(13)61903-0
pubmed: 24581682
pmcid: 4069226
Mehrotra R, Tulsyan S, Hussain S, Mittal B, Singh Saluja S, Singh S, et al. Genetic landscape of gallbladder cancer: global overview. Mutat Res Rev Mutat Res. 2018;778:61–71. https://doi.org/10.1016/j.mrrev.2018.08.003 .
doi: 10.1016/j.mrrev.2018.08.003
pubmed: 30454684
Gkika E, Hawkins MA, Grosu AL, Brunner TB. The evolving role of radiation therapy in the treatment of biliary tract cancer. Front Oncol. 2020;10:604387. https://doi.org/10.3389/fonc.2020.604387 .
doi: 10.3389/fonc.2020.604387
pubmed: 33381458
pmcid: 7768034
Simo KA, Halpin LE, McBrier NM, Hessey JA, Baker E, Ross S, et al. Multimodality treatment of intrahepatic cholangiocarcinoma: a review. J Surg Oncol. 2016;113:62–83. https://doi.org/10.1002/jso.24093 .
doi: 10.1002/jso.24093
pubmed: 26797780
Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31:1188–95. https://doi.org/10.1200/jco.2012.41.5984 .
doi: 10.1200/jco.2012.41.5984
pubmed: 23358969
Song S, Kim K, Chie EK, Kim S, Park HJ, Yi NJ, et al. Locoregional recurrence after curative intent resection for intrahepatic cholangiocarcinoma: implications for adjuvant radiotherapy. Clin Transl Oncol. 2015;17:825–9. https://doi.org/10.1007/s12094-015-1312-0 .
doi: 10.1007/s12094-015-1312-0
pubmed: 26041722
Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol. 2011;18:651–8. https://doi.org/10.1245/s10434-010-1325-4 .
doi: 10.1245/s10434-010-1325-4
pubmed: 20945107
Brunner TB, Seufferlein T. Radiation therapy in cholangiocellular carcinomas. Best Pract Res Clin Gastroenterol. 2016;30:593–602. https://doi.org/10.1016/j.bpg.2016.08.003 .
doi: 10.1016/j.bpg.2016.08.003
pubmed: 27644907
Sahai P, Kumar S. External radiotherapy and brachytherapy in the management of extrahepatic and intrahepatic cholangiocarcinoma: available evidence. Br J Radiol. 2017;90:20170061. https://doi.org/10.1259/bjr.20170061 .
doi: 10.1259/bjr.20170061
pubmed: 28466653
pmcid: 5603950
Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30:1934–40. https://doi.org/10.1200/jco.2011.40.5381 .
doi: 10.1200/jco.2011.40.5381
pubmed: 22529261
Liang H, Wang Y, Chen J, Xing J, Pu Y. The efficacy of adjuvant chemoradiotherapy in early-stage gallbladder adenocarcinoma depends on the tumor invasion depth and differentiation level. Front Oncol. 2020;10:616170. https://doi.org/10.3389/fonc.2020.616170 .
doi: 10.3389/fonc.2020.616170
pubmed: 33392099
pmcid: 7775593
Glazer ES, Liu P, Abdalla EK, Vauthey JN, Curley SA. Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins. J Gastrointest Surg. 2012;16:1666–71. https://doi.org/10.1007/s11605-012-1935-1 .
doi: 10.1007/s11605-012-1935-1
pubmed: 22777053
Bonet Beltrán M, Allal AS, Gich I, Solé JM, Carrió I. Is adjuvant radiotherapy needed after curative resection of extrahepatic biliary tract cancers? A systematic review with a meta-analysis of observational studies. Cancer Treat Rev. 2012;38:111–9. https://doi.org/10.1016/j.ctrv.2011.05.003 .
doi: 10.1016/j.ctrv.2011.05.003
pubmed: 21652148
Choi SH, Rim CH, Shin IS, Yoon WS, Koom WS, Seong J. Adjuvant radiotherapy for extrahepatic cholangiocarcinoma: a quality assessment-based meta-analysis. Liver Cancer. 2021;10:419–32. https://doi.org/10.1159/000518298 .
doi: 10.1159/000518298
pubmed: 34721505
pmcid: 8527906
Wang SJ, Fuller CD, Kim JS, Sittig DF, Thomas CR Jr, Ravdin PM. Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer. J Clin Oncol. 2008;26:2112–7. https://doi.org/10.1200/jco.2007.14.7934 .
doi: 10.1200/jco.2007.14.7934
pubmed: 18378567
Ren B, Guo Q, Yang Y, Liu L, Wei S, Chen W, et al. A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma. Radiat Oncol. 2020;15:15. https://doi.org/10.1186/s13014-020-1459-x .
doi: 10.1186/s13014-020-1459-x
pubmed: 31941520
pmcid: 6964081
Kim BH, Kwon J, Chie EK, Kim K, Kim YH, Seo DW, et al. Adjuvant chemoradiotherapy is associated with improved survival for patients with resected gallbladder carcinoma: a systematic review and meta-analysis. Ann Surg Oncol. 2018;25:255–64. https://doi.org/10.1245/s10434-017-6139-1 .
doi: 10.1245/s10434-017-6139-1
pubmed: 29079926
Gold DG, Miller RC, Haddock MG, Gunderson LL, Quevedo F, Donohue JH, et al. Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience. Int J Radiat Oncol Biol Phys. 2009;75:150–5. https://doi.org/10.1016/j.ijrobp.2008.10.052 .
doi: 10.1016/j.ijrobp.2008.10.052
pubmed: 19297105
Wang SJ, Lemieux A, Kalpathy-Cramer J, Ord CB, Walker GV, Fuller CD, et al. Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol. 2011;29:4627–32. https://doi.org/10.1200/jco.2010.33.8020 .
doi: 10.1200/jco.2010.33.8020
pubmed: 22067404
pmcid: 3236647
Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33:2617–22. https://doi.org/10.1200/jco.2014.60.2219 .
doi: 10.1200/jco.2014.60.2219
pubmed: 25964250
Benson AB 3rd, D’Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, et al. NCCN guidelines insights: hepatobiliary cancers, version 1.2017. J Natl Compr Canc Netw. 2017;15:563–73. https://doi.org/10.6004/jnccn.2017.0059 .
doi: 10.6004/jnccn.2017.0059
pubmed: 28476736
pmcid: 5557008
Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37:1015–27. https://doi.org/10.1200/jco.18.02178 .
doi: 10.1200/jco.18.02178
pubmed: 30856044
Borakati A, Froghi F, Bhogal RH, Mavroeidis VK. Stereotactic radiotherapy for intrahepatic cholangiocarcinoma. World J Gastrointest Oncol. 2022;14(8):1478–89. https://doi.org/10.4251/wjgo.v14.i8.1478 .
doi: 10.4251/wjgo.v14.i8.1478
pubmed: 36160742
pmcid: 9412934
Kim J, Jung Y. Radiation-induced liver disease: current understanding and future perspectives. Exp Mol Med. 2017;49(7):e359. https://doi.org/10.1038/emm.2017.85 .
doi: 10.1038/emm.2017.85
pubmed: 28729640
pmcid: 5565955